Secondary analysis of the phase 3 FLAIR trial in untreated CLL: quality-of-life trajectories were similar with ibrutinib-rituximab vs FCR; FCR scores were worse at end of treatment but recovered, and differences did not exceed minimally important thresholds.
Secondary analysis
Allsup et al. Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab